Publications by authors named "E D Capoluongo"
Background: Ovarian cancer (OvC) constitutes significant management challenges primarily due to its late-stage diagnosis and the development of resistance to chemotherapy. The standard treatment regimen typically includes carboplatin and paclitaxel, with the addition of poly (ADP-ribose) polymerase inhibitors for patients with high-grade serous ovarian cancer (HGSOC) harboring BRCA1/2 mutations. However, the variability in treatment responses suggests the need to investigate factors beyond BRCA1/2 mutations, such as DNA repair mechanisms and epigenetic alterations.
View Article and Find Full Text PDFArticle Synopsis
- This paper talks about problems in cancer treatment in Europe, especially how health guidelines and medical recommendations don’t match up.
- It studied different European countries to see if they use advanced cancer tests that doctors recommend.
- The results showed that many countries are not using these advanced tests, which could help patients more, and the paper suggests that health leaders need to pay more attention to these recommendations for better cancer care.
Precancerous and cancerous lesions of the uterine cervix are known to be associated with Human Papillomavirus (HPV) infection. The screening of high-risk (HR)-HPV infection in the female population has led to the discovery of several cases of a double cervix, a congenital malformation that is very rare. The purpose of this study was to evaluate HR-HPV infections in women with a double cervix within the National Cervical Cancer Screening program of the Lazio region (Italy).
View Article and Find Full Text PDFArticle Synopsis
- European health systems can improve health by using more technology to prevent diseases and spot them early.
- Right now, they're not using these tools effectively, which means patients aren't getting the best diagnosis or access to new treatments.
- The study looks into how different countries in Europe are handling new health technologies and genetics, and suggests it's a good time to rethink how to use these tools better in healthcare.
Article Synopsis
- CFTR modulators have changed the way sweat tests (ST) for cystic fibrosis (CF) are viewed, allowing their use as an outcome measure, but the tests still require strict adherence to guidelines due to operator dependency.
- The Italian CF Society launched a new specific ST report in 2022, impacting the external quality assessment program (I-EQA-SCT) for sweat tests during the 2022-23 round, which included cases related to patients on CFTR modulators.
- Results showed that while many labs improved in their performance, some struggled with interpreting cases involving modulators and using updated report formats, highlighting the need for ongoing quality assessment and adherence to the latest recommendations.